Seattle Genetics/ US81181C1045 /
2023-12-13 9:59:59 PM | Chg. - | Volume | Bid1:50:00 AM | Ask1:50:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
228.91USD | - | 884,364 Turnover: 145.25 mill. |
-Bid Size: - | -Ask Size: - | 43.15 bill.USD | - | - |
GlobeNewswire
03-04
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...
GlobeNewswire
2022-03-14
Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate ...
GlobeNewswire
2022-01-18
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
GlobeNewswire
2022-01-10
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
GlobeNewswire
2021-11-15
Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and De...
GlobeNewswire
2021-10-26
Harpoon Therapeutics Announces Change to Management Team and Board of Directors
GlobeNewswire
2021-10-14
Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Upda...
GlobeNewswire
2021-08-25
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
GlobeNewswire
2021-07-13
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Upd...
GlobeNewswire
2021-06-01
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors
GlobeNewswire
2020-09-21
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurr...
GlobeNewswire
2020-09-10
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors